FAILED TRIAL: Ph 2 AMPLIFY-7P trial did not meet the pre-specified primary endpoint of DFS in the ITT adjuvant pancreatic cancer population June 17, 2026
FDA accepted supplemental BLA filing for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemo in stage III dMMR or MSI-H colon cancer and granted Priority Review; PDUFA: 9 October 2026 June 17, 2026
Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy June 17, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer June 10, 2026
Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
IBI343 (arcotatug tavatecan) Met Primary Endpoint in Ph 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA June 10, 2026
FDA Orphan Drug Designation Granted to Oxaliplatin for the Treatment of Pancreatic Cancer June 2, 2026
FDA Accepts NDA with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST June 2, 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline May 21, 2026
Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan in Gastrointestinal Tumors May 21, 2026
FDA cleared IND for Ph 1/2 study of oral elraglusib in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers May 12, 2026
Study initiated to evaluate Pidnarulex (CX-5461) + tislelizumab in pancreatic cancer, colorectal cancer, and melanoma May 12, 2026
FDA Commissioner’s National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma May 12, 2026
FDA Approves BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher May 12, 2026
Tovecimig Demonstrates Statistically Significant PFS Benefit but misses the OS benefit in COMPANION-002 Ph 2/3 Study in Patients with Biliary Tract Cancer May 6, 2026
FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer May 6, 2026
